Capricor Therapeutics (CAPR)

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is Deramiocel, an allogeneic cardiosphere-derived cell therapy, which is in phase 3 clinical trial for the treatment of DMD. The company also develops an exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2. The StealthX Exosome Platform consists of engineered exosomes for vaccine and therapeutic development and is currently in preclinical trial. In addition, it is developing StealthX, an engineered exosome-based vaccine candidate, which is under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. Capricor is also working on CAP-2003, an allogeneic cardiosphere-derived cells-exosome therapy, which is in preclinical trial to treat DMD. The company has license agreements with Johns Hopkins University, University of Rome, and Cedars-Sinai Medical Center to develop and commercialize licensed products and services under the licensed patent rights in all fields, as well as a nonexclusive right to the know-how. Additionally, it has a Cell Line License Agreement with Life Technologies for the development of its exosome platform. The company was founded in 2005 and is headquartered in San Diego, California.